Masking
toxicity, allergy
ALLERGY
The code of each participant is given to pharmacists who are involved in the study. The pharmacists keep the code in the sealed envelope. Researchers, doctors, and participants do not know the results of randomization. The drug and placebo capsules are administered to patients by a staff member who is privy to the treatment. Each participant should return the unused capsules every month. At the end of the study, the pharmacist and related staff members will count the Medication Possession Ratio (MPR). The study will be discontinued if:the participant withdraws informed consentthe participant develops significant toxicity, intolerance or allergy associated with study drug that causes a risk to participant’s lifethe participant is admitted to hospital for other morbidity that is incompatible with further atorvastatin treatmentblinding is revealed. Unblinding will also be available if a clinician believes that clinical management depends importantly on knowledge of whether the patient is currently receiving statin or placebo.